Newsfeeds - Spark Newswire

1 minute read

10-Year Phase 3 Trial Shows CEL-SCI’s Multikine immunotherapy Extends Lives In Head & Neck Cancer Patients

Today, 11:01 AM

CEL-SCI Corporation (NYSE:CVM) said that its 10-year Phase 3 trial showed that Multikine immunotherapy significantly extended the lives of patients with…

BMS

4 minute read

The Daily Biotech Pulse: Avenue Tumbles On Negative Adcom Verdict, Moderna’s Expanded Deal With Rovi, Gilead Takes Equity Stake In Hookipa

By Shanthi Rexaline

Today, 11:01 AM

Here's a roundup of top developments in the biotech space over the last 24 hours.

ALKS

1 minute read

AstraZeneca’s Saphnelo For Lupus Treatment Approved In Japan

By Vandana Singh

Today, 11:01 AM

The Japanese Ministry of Health, Labor and Welfare (MHLW) has approved AstraZeneca plc’s (NASDAQ:AZN) Saphnelo (anifrolumab) for systemic lupus erythematosus (SLE),…

AZN